FAQ: Cybin Inc.'s US$175M Registered Direct Offering and Company Overview
Summary
Cybin Inc. announced a US$175 million registered direct offering of common shares and pre-funded warrants priced at US$6.51 per share, with participation from prominent healthcare and biotech investors. This significant capital raise supports the company's late-stage development of novel neuropsychiatry treatments, including CYB003 for major depressive disorder which has received FDA Breakthrough Therapy Designation.
What is the main announcement in this content?
Cybin Inc. announced a registered direct offering of 22,277,750 common shares and pre-funded common share purchase warrants priced at US$6.51 per share, generating aggregate gross proceeds of US$175,009,911.45 from new and existing investors.
What are the key terms of the warrants included in this offering?
Each share or pre-funded warrant comes with 0.35 of one common share purchase warrant exercisable at US$8.14 per share until the earlier of June 30, 2027, 30 days after topline data release for the APPROACH trial of CYB003 in major depressive disorder, or 30 days after an acceleration notice if the NYSE American closing price equals or exceeds US$19.53 for five consecutive trading days.
Which investors are participating in this offering?
Participants include both new and existing investors such as Venrock Healthcare Capital Partners, OrbiMed, Point72, Deep Track Capital, Acorn Bioventures, Spruce Street Capital, Squadron Capital Management, Adage Capital Partners LP, Boxer Capital Management, ADAR1 Capital Management, Stonepone Capital Management, Pivotal Bioventure Partners and Ally Bridge Group.
What is Cybin Inc. and what does the company do?
Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
What are Cybin’s key development programs mentioned in the content?
Cybin is developing CYB003, a proprietary deuterated psilocin analog in Phase 3 studies for adjunctive treatment of major depressive disorder (with FDA Breakthrough Therapy Designation), and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in Phase 2 study for generalized anxiety disorder, plus a research pipeline of 5-HT-receptor focused compounds.
Where can I find more detailed information about this offering?
The full press release is available at https://ibn.fm/TPxvo, and the latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN.
Where does Cybin operate geographically?
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland.
What is the significance of the FDA Breakthrough Therapy Designation mentioned?
CYB003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, which indicates the FDA recognizes its potential to demonstrate substantial improvement over available therapies for major depressive disorder and may expedite its development and review.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 272471